Abbvie Inc. (NYSE:ABBV) said late Wednesday it expects its Q1 per-share adjusted earnings to take a $0.08 hit from acquired in-process research and development and milestones expense of $150 million on a pre-tax basis.
The company expects Q1 adjusted EPS of $2.31 to $2.41, including the impact, according to a regulatory filing. Analysts surveyed by Capital IQ project $2.56 per share.
For 2023, AbbVie said it now expects adjusted EPS of $10.62 to $11.02, compared with its prior range of $10.70 to $11.10.
Analysts polled by Capital IQ expect $11.07 per share.